Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 7:15:1659-1667.
doi: 10.2147/JPR.S365954. eCollection 2022.

The Tourniquet Ischemia Test Effectively Predicts the Efficacy of Lumbar Sympathetic Block in Patients with Lower Extremity Complex Regional Pain Syndrome Type 1

Affiliations

The Tourniquet Ischemia Test Effectively Predicts the Efficacy of Lumbar Sympathetic Block in Patients with Lower Extremity Complex Regional Pain Syndrome Type 1

Yongming Xu et al. J Pain Res. .

Abstract

Background: Neuropathic pain is the most common clinical sign of complex regional pain syndrome (CRPS). Currently, lumbar sympathetic block (LSB) is commonly utilized in lower extremity CRPS that has failed to respond to medication therapy and physical therapy, but its effectiveness is unknown. The tourniquet ischemia test (IT) can distinguish between two types of CRPS: IT-positive CRPS and IT-negative CRPS.

Objective: The aim of the study was to investigate whether LSB improves pain scores in patients with lower extremity CRPS-1 and to screen factors to predict its efficacy.

Study design: Prospective clinical observational study.

Setting: Pain management center.

Subjects: Forty-three patients diagnosed with lower extremity CRPS-1 using the Budapest criteria were included as participants.

Methods: Forty-three CRPS-1 patients were treated with LSB therapy, and all of them underwent a tourniquet ischemia test (IT) before undergoing LSB therapy. LSB therapy was performed using a combination of ultrasonography and fluoroscopy. Then, numeric rating scale (NRS) scores and the symptom relief rates of patients were evaluated at 1, 4, and 12 weeks. Finally, peripheral blood inflammatory cytokine samples were collected before and after the LSB treatment.

Results: At 4 weeks after the treatment, the total effective symptom relief rate of LSB on CRPS-1 was 25.6% (11/43), with 52.6% (10/19) of IT(+) patients and 4.2% (1/24) of IT(-) patients. There was a significant difference between the IT(-) and IT(+) groups (P = 0.001). The multivariate binary logistic regression analysis revealed that the response to the tourniquet IT was the only significant independent predictor of sympathetic block success (p = 0.007).

Conclusion: Tourniquet IT is a simple, safe and effective test to distinguish patients with lower extremity CRPS-1. The response to the tourniquet IT is a reliable predictor of LSB effectiveness in lower extremity CRPS-1 patients.

Keywords: complex regional pain syndrome; lumbar sympathetic block; predict; tourniquet ischemia test.

PubMed Disclaimer

Conflict of interest statement

All authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow chart.
Figure 2
Figure 2
Ultrasound-guided lumbar sympathetic block. (A) An ultrasound probe was used to scan the lumbar sympathetic nerve of the patient while in the lateral position. (B) Ultrasonic image of the lumbar paravertebral region at the L3 vertebral level. 1, lumbar vertebra; 2, lumbar transverse process; 3, abdominal aorta; 4, psoas major; 5, psoas quadratus muscle; 6, erector spinalis muscle; 7, kidney. Arrowheads point to the anterior fascia of the psoas quadratus muscle.
Figure 3
Figure 3
Location of the needle tip and contrast under AP/lateral fluoroscopy. (A) The needle tip should lie medial to the lateral margin of the vertebral body in the AP projection, and the contrast spreads over the surface of the vertebral body. (B) The needle tip should be positioned over the anterior one-third of the vertebral body in the lateral position, and the contrast spreads over the surface of the vertebral body.
Figure 4
Figure 4
Illustration of clinical success rates at different time points after the injection. IT-: IT(-) group, IT+: IT(+) group. * P<0.05, compared with IT(-) group.

Similar articles

References

    1. Harden NR, Bruehl S, Perez R, et al. Validation of proposed diagnostic criteria (the “Budapest Criteria”) for Complex Regional Pain Syndrome. Pain. 2010;150:268–274. - PMC - PubMed
    1. de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC. The incidence of complex regional pain syndrome: a population-based study. Pain. 2007;129:12–20. - PubMed
    1. Dworkin RH, O’Connor AB, Kent J, et al. Interventional management of neuropathic pain: neuPSIG recommendations. Pain. 2013;154:2249–2261. - PMC - PubMed
    1. Kessler A, Yoo M, Calisoff R. Complex regional pain syndrome: an updated comprehensive review. NeuroRehabilitation. 2020;47:253–264. - PubMed
    1. Iolascon G, Moretti A. Pharmacotherapeutic options for complex regional pain syndrome. J Med. 2019;20:1377–1386. - PubMed